Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
PLoS One. 2022 Jan 7;17(1):e0262455. doi: 10.1371/journal.pone.0262455. eCollection 2022.
Nivolumab, an immune checkpoint blocker, has been approved for advanced gastric cancer (GC), but predictive factors of nivolumab's efficacy in patients with GC, especially immune cells such as tissue-resident memory T cells or those forming tertiary lymphoid structures (TLS), remain unclear. Tissue samples were obtained from surgically resected specimens of patients with GC who were treated with nivolumab as third-line or later treatment. Immunohistochemical staining was performed to detect the presence of TLS and CD103+ T cells and assess the association between TLSs and response to nivolumab treatment. A total of 19 patients were analyzed. In patients with partial response (PR) to nivolumab, numerous TLS were observed, and CD103+ T cells were found in and around TLS. Patients with many TLS experienced immune-related adverse events more often than those with few TLS (p = 0.018). The prognosis of patients with TLS high was better than those with TLS low. Patients with a combination of TLS high and CD103 high tended to have a better prognosis than other groups. Our results suggested that TLS status might be a predictor of nivolumab effectiveness.
纳武利尤单抗（一种免疫检查点抑制剂）已被批准用于治疗晚期胃癌（GC），但纳武利尤单抗在 GC 患者中的疗效的预测因素，尤其是免疫细胞（如组织驻留记忆 T 细胞或形成三级淋巴结构（TLS）的细胞）仍不清楚。本研究从接受纳武利尤单抗三线或以上治疗的 GC 患者的手术切除标本中获得组织样本。进行免疫组织化学染色以检测 TLS 和 CD103+T 细胞的存在，并评估 TLS 与纳武利尤单抗治疗反应之间的关系。共分析了 19 例患者。在对纳武利尤单抗有部分缓解（PR）的患者中，观察到大量的 TLS，并且在 TLS 内和周围发现了 CD103+T 细胞。与 TLS 少的患者相比，TLS 多的患者更常发生免疫相关不良事件（p=0.018）。TLS 高的患者的预后好于 TLS 低的患者。TLS 高和 CD103 高的患者组合倾向于有更好的预后。我们的研究结果表明，TLS 状态可能是纳武利尤单抗疗效的预测因素。
